Sildenafil (PAH) — $0 with Membership

Other medications in Heart & Cardiovascular

• Simvastatin
• Sotalol
• Tadalafil (PAH)
• Telmisartan
• Ticagrelor
• Torsemide
• Trandolapril
• Treprostinil

About Sildenafil (PAH)

Sildenafil PAH is a vital medication prescribed to treat Pulmonary Arterial Hypertension (PAH), a serious condition affecting the lungs and heart. Understanding its role and how to manage prescription costs is crucial. TheDrugClub is dedicated to helping members like you access important medications like Sildenafil PAH more affordably, offering significant savings on your prescriptions.

Pulmonary Arterial Hypertension (PAH) is a chronic and progressive condition characterized by high blood pressure in the arteries leading from the heart to the lungs. This elevated pressure makes the heart work harder to pump blood, which can lead to symptoms like shortness of breath, fatigue, chest pain, and swelling in the legs. If left untreated, PAH can severely impact quality of life and lead to heart failure.

What Sildenafil PAH Treats

Sildenafil PAH is specifically approved to treat Pulmonary Arterial Hypertension. It aims to improve exercise capacity and slow the progression of the disease, helping patients live more comfortably and actively. It's important to note that while the active ingredient sildenafil is also used for erectile dysfunction, Sildenafil PAH is prescribed in different dosages and formulations tailored for PAH treatment.

How Sildenafil PAH Works

Sildenafil PAH belongs to a class of medications called phosphodiesterase-5 (PDE5) inhibitors. Its primary mechanism of action involves relaxing the smooth muscle cells in the walls of the pulmonary arteries. By inhibiting the PDE5 enzyme, sildenafil allows for an increase in a substance called cyclic guanosine monophosphate (cG

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sildenafil (PAH) is approved for (FDA label)

Sildenafil tablets are indicated for the treatment of erectile dysfunction. Sildenafil tablet is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) (1)

Source: Read the full FDA label on DailyMed. Label effective date: August 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sildenafil (PAH) (FDA label)

Sildenafil Tablets USP, 25 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'I' on one side and '35' on the other side. Sildenafil Tablets USP, 50 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'I' on one side and '36' on the other side. Sildenafil Tablets USP, 100 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'I' on one side and '58' on the other side. Tablets: 25 mg, 50 mg, 100 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: 174ef537-e3e6-42bd-a478-47b930ddc761. SPL document ID: 28fbd804-8f01-4e84-aba8-76ad8614fb99. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sildenafil (PAH) (FDA label)

The following are discussed in more detail in other sections of the labeling: • Cardiovascular [see Warnings and Precautions (5.1)] • Prolonged Erection and Priapism [see Warnings and Precautions (5.2)] • Effects on the Eye [see Warnings and Precautions (5.3)] • Hearing Loss [ see Warnings and Precautions (5.4)] • Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions (5.5)] • Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions (5.6)] • Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions (5.7)] • Effects on Bleeding [see Warnings and Precautions (5.8)] • Counseling Patients About Sexually Transmitted Diseases [see Warnings and Precautions (5.9)] The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.

Source: FDA prescribing information (DailyMed). Set ID: 174ef537-e3e6-42bd-a478-47b930ddc761. SPL document ID: 28fbd804-8f01-4e84-aba8-76ad8614fb99. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sildenafil (PAH) (FDA label)

• Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets were shown to potentiate the hypotensive effect of nitrates ( 4.1 , 7.1 , 12.2 ) • Known hypersensitivity to sildenafil or any component of tablet (4.2) • Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway [ see Clinical Pharmacology ( 12.1 , 12.2)] , sildenafil tablets were shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered.

Source: FDA prescribing information (DailyMed). Set ID: 174ef537-e3e6-42bd-a478-47b930ddc761. SPL document ID: 28fbd804-8f01-4e84-aba8-76ad8614fb99. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sildenafil (PAH) (FDA label)

• Patients should not use sildenafil tablets if sexual activity is inadvisable due to cardiovascular status (5.1) • Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil tablets with caution in patients predisposed to priapism (5.2) • Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Sildenafil tablets should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a ”crowded” optic disc may also be at an increased risk of NAION. (5.3) • Patients should stop sildenafil tablets and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.4) • Caution is advised when sildenafil tablets are co-administered with alpha-blockers or anti-hypertensives.

Source: FDA prescribing information (DailyMed). Set ID: 174ef537-e3e6-42bd-a478-47b930ddc761. SPL document ID: 28fbd804-8f01-4e84-aba8-76ad8614fb99. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sildenafil (PAH) (FDA label)

• Sildenafil tablets can potentiate the hypotensive effects of nitrates, alpha blockers, and anti-hypertensives ( 4.1 , 5.5 , 7.1 , 7.2 , 7.3 , 12.2 ) • With concomitant use of alpha blockers, initiate sildenafil tablets at 25 mg dose (2.3) • CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin): Increase sildenafil tablets exposure (2.4 , 7.4 , 12.3 ) • Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48 hour period ( 2.4 , 5.6) • Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg (2.4, 7.4) 7.1 Nitrates Administration of sildenafil tablets with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated.

Source: FDA prescribing information (DailyMed). Set ID: 174ef537-e3e6-42bd-a478-47b930ddc761. SPL document ID: 28fbd804-8f01-4e84-aba8-76ad8614fb99. Label effective date: August 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.